精準腫瘤學市場規模、佔有率和成長分析：按產品類型、技術、癌症類型、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球精準腫瘤學市場價值為 1,200 億美元，預計到 2025 年將成長至 2033 年的 2,715.9 億美元，在預測期（2026-2033 年）內複合年成長率為 9.5%。

精準腫瘤學市場的主要驅動力是高通量基因組技術與標靶治療的融合，從而在分子診斷和治療策略之間建立直接聯繫。這種方法能夠根據個別腫瘤的生物學特徵量身訂做癌症治療方案，圖治療反應率並降低毒性。從單基因檢測到全面的次世代定序panel以及液態生物檢體的引入，標誌著該市場的演進。此外，基因組數據、臨床記錄和真實世界數據（REW）的日益融合，透過促進罕見目標的發現和高效的臨床試驗匹配，正在推動市場成長。次世代定序的保險報銷政策的進步以及液態生物檢體活體組織切片在病患監測中應用的增加，正在推動對人工智慧驅動的決策支援系統的投資，最終擴大市場准入，並在不同地區建立可擴展的治療路徑。

全球精準腫瘤學市場促進因素

全球精準腫瘤學市場正受到基因組分析技術進步的顯著推動，這些技術能夠更精準地識別腫瘤特異性分子特徵。這些進步使得患者分層和標靶治療選擇更加準確，增強了臨床對個人化治療方案的信心。隨著診斷檢測手段的日益完善和生物標記解釋的不斷改進，相關人員對精準腫瘤學價值的認知不斷提高，促使他們對診斷平台和伴隨檢測的投資不斷增加。這一趨勢不僅提升了服務水平，也促進了精準腫瘤學與標準醫療保健體系的融合，進一步鞏固了其在現代醫療保健中的重要地位。

全球精準腫瘤學市場面臨的限制因素

全球精準腫瘤學市場面臨許多挑戰，其中最主要的原因是先進基因組檢測高成本且需要專門的檢測設施。此外，生物資訊學和專業人才方面的持續投入也會限制這些技術的應用，尤其是在預算緊張的情況下。不斷上漲的單次檢測成本以及保險報銷的不確定性進一步降低了醫療機構常規採用這些技術的意願，導致醫療服務提供者更傾向於傳統的診斷方法。這些對檢查室和醫療機構帶來的經濟負擔可能會阻礙檢測服務的成長，並妨礙精準腫瘤學融入標準臨床實踐，最終限制市場擴張和醫療服務的可及性。

全球精準腫瘤學市場趨勢

全球精準腫瘤學市場正呈現出向綜合多體學整合的顯著趨勢，這種整合透過整合基因組學、轉錄組學、蛋白質組學和代謝組學數據，正在變革傳統的診斷方法。這種整體觀點增強了患者分層，實現了更精準的治療方法匹配，並擺脫了對單一標記診斷的依賴。跨平台檢測和廣泛的檢查室網路的建立，加速了更豐富生物標記的發現，而統一的數據標準和可互通的流程則有助於改善臨床決策。隨著診斷開發商、製藥公司和臨床中心等相關人員之間合作的日益緊密，整合服務和基於價值的模式正在湧現，為全球精準腫瘤學領域創造了新的機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球精準腫瘤學市場規模：依產品類別分類

• 診斷
• 治療
• 數據分析軟體
• 其他

全球精準腫瘤學市場規模：依技術分類

• 次世代定序（NGS）
• 聚合酵素鏈鎖反應（PCR）
• 原位雜合反應（ISH）
• 免疫組織化學（IHC）
• 微陣列
• 其他

全球精準腫瘤學市場規模：依癌症類型分類

• 乳癌
• 肺癌
• 結腸癌
• 攝護腺癌
• 血癌
• 其他

全球精準腫瘤學市場規模：依應用領域分類

• 診斷
• 藥物發現和臨床試驗
• 個人化治療方案
• 預後
• 其他

全球精準腫瘤學市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 製藥和生物技術公司
• 研究和學術機構

全球精準腫瘤學市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche
• Illumina
• Pfizer
• Novartis
• AstraZeneca
• Bristol Myers Squibb
• AbbVie
• Johnson & Johnson
• Gilead Sciences
• Merck & Co.
• Amgen
• QIAGEN
• Thermo Fisher Scientific
• Guardant Health
• Myriad Genetics
• Tempus
• Foundation Medicine
• Caris Life Sciences
• Exact Sciences
• Bio-Rad Laboratories

結論與建議

Global Precision Oncology Market size was valued at USD 120.0 Billion in 2024 and is poised to grow from USD 131.4 Billion in 2025 to USD 271.59 Billion by 2033, growing at a CAGR of 9.5% during the forecast period (2026-2033).

The precision oncology market is primarily driven by the integration of high-throughput genomic technologies and targeted therapies, creating a direct connection between molecular diagnostics and treatment strategies. This approach tailors cancer care to individual tumor biology, enhancing response rates and minimizing toxicity. The shift from single-gene tests to comprehensive next-generation sequencing panels, coupled with liquid biopsies, exemplifies the market's evolution. Growth is further supported by the integration of data across genomics, clinical records, and real-world evidence, facilitating the discovery of rare targets and efficient trial matching. Advances in reimbursement for next-generation sequencing and the increased use of liquid biopsies for patient monitoring attract investment in AI-driven decision support, ultimately expanding market access and creating scalable pathways in diverse regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Oncology Market Segments Analysis

Global precision oncology market is segmented by product, technology, cancer type, application, end-user and region. Based on product, the market is segmented into Diagnostics, Therapeutics, Data Analytics & Software and Others. Based on technology, the market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Microarray and Others. Based on cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancers and Others. Based on application, the market is segmented into Diagnostics, Drug Development & Clinical Trials, Personalized Treatment Selection, Prognostics and Others. Based on end-user, the market is segmented into Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies and Research & Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Oncology Market

The Global Precision Oncology market is significantly driven by advancements in genomic profiling technologies that enhance the identification of tumor-specific molecular signatures. This progress facilitates more accurate patient stratification and selection of targeted therapies, increasing clinical confidence in personalized treatment options. As diagnostic assays become more comprehensive and biomarker interpretation improves, the perceived value of precision oncology rises among stakeholders, leading to increased investment in diagnostic platforms and companion tests. This trend not only bolsters the expansion of service offerings but also promotes the integration of precision oncology into standard care practices, further solidifying its role in modern healthcare.

Restraints in the Global Precision Oncology Market

The Global Precision Oncology market faces significant challenges due to the high costs linked to advanced genomic assays and the need for specialized laboratory facilities. Additionally, the ongoing investment required in bioinformatics and skilled labor can restrict the adoption of these technologies, particularly in settings with limited budgets. Elevated per-test costs and uncertainties surrounding reimbursement further diminish the motivation for routine adoption, causing healthcare providers to favor traditional diagnostic methods. This financial strain on laboratories and healthcare institutions may hinder the growth of testing services and disrupt the integration of precision oncology into standard clinical practices, ultimately restricting market expansion and accessibility.

Market Trends of the Global Precision Oncology Market

The Global Precision Oncology market is witnessing a significant trend towards comprehensive multi-omics integration, where the convergence of genomic, transcriptomic, proteomic, and metabolomic data is transforming traditional diagnostic approaches. This holistic perspective enables enhanced patient stratification and more precise therapeutic matching, moving away from reliance on single-marker diagnostics. The establishment of cross-platform assays and expansive laboratory networks is fostering richer biomarker discovery, while aligned data standards and interoperable pipelines are improving clinical decision-making. As stakeholders-including diagnostics developers, pharmaceutical companies, and clinical centers-collaborate more closely, integrated services and value-based models are emerging, creating new opportunities in precision oncology across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Precision Oncology Market Size by Product & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Therapeutics
• Data Analytics & Software
• Others

Global Precision Oncology Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• In Situ Hybridization (ISH)
• Immunohistochemistry (IHC)
• Microarray
• Others

Global Precision Oncology Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers
• Others

Global Precision Oncology Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Drug Development & Clinical Trials
• Personalized Treatment Selection
• Prognostics
• Others

Global Precision Oncology Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes

Global Precision Oncology Market Size & CAGR (2026-2033)

• North America (Product, Technology, Cancer Type, Application, End-User)
  • US
  • Canada
• Europe (Product, Technology, Cancer Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Cancer Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Cancer Type, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Cancer Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations